Pharma BD Deal Intelligence
Deciphera Pharmaceuticals to be acquired by ONO Pharmaceutical for $2.4 billion at $25.60 per share a 74.7 percent premium adding QINLOCK and vimseltinib…
Ono acquired Deciphera for $2.4B for Qinlock (ripretinib) for GI stromal tumors.
Deciphera receives European Commission approval of ROMVIMZA (vimseltinib) for the treatment of tenosynovial giant cell tumor (TGCT), September 17, 2025 -- the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Ono Pharmaceutical acquired Deciphera Pharmaceuticals for approximately $2.4 billion ($25.60/share cash, a 74.7% premium), announced April 29, 2024 and closed June 11, 2024 via tender offer, making Deciphera a wholly owned Ono subsidiary. The deal gave Ono its lead commercial asset QINLOCK (ripretinib), a switch-control KIT/PDGFRA inhibitor approved for fourth-line GIST (full-year 2023 net product revenue $159.1M), plus the late-stage candidate vimseltinib, an oral CSF1R inhibitor for tenosynovial giant cell tumor (TGCT), establishing Ono a U.S. and European commercial oncology footprint. The vimseltinib thesis has since been realized: the FDA granted full approval of ROMVIMZA (vimseltinib) for symptomatic TGCT on February 14, 2025 -- the second approved drug from Deciphera's switch-control kinase platform -- followed by European Commission approval on September 17, 2025, where it is the first and only authorized TGCT therapy. The acquisition's growing-portfolio rationale is intact and de-risked, with two approved commercial products across the U.S. and EU.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ono Pharmaceutical Co., Ltd. / Deciphera Pharmaceuticals (this deal) | 2024 | $2.4B | 69 |
| Ono Pharmaceutical Co., Ltd. / Ionis Pharmaceuticals, Inc. | 2025 | $940M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2024 deals · Oncology deals